Effect of new combined medication “Young Prostate" on clinical symptoms in patients with benign prostate hypertrophy and overactive bladder

Effect of new combined medication “Young Prostate" versus standard treatment on clinical symptoms in patients with benign prostate hypertrophy and overactive bladder: a randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N386

Enrollment

Registered

2021-03-07

Start date

2021-04-04

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostate hypertrophy. Benign neoplasm of prostate

Interventions

Intervention 1: Intervention group: New combined tablet “Young prostate” (containing Trazosin 2 mg, Finasteride 5 mg, and Oxybutynin5 mg) daily for 6 months. Intervention 2: Control group: Tablets Fin

Eligibility

Sex/Gender

Male

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age of 40 to 65 years Benign prostate hypertrophy Overactive bladder

Exclusion criteria

Exclusion criteria: History of prostate surgery

Design outcomes

Primary

Measure	Time frame
Sexual desire. Timepoint: Before the intervention and 3 and 6 months after that. Method of measurement: By taking history.;Prostate size. Timepoint: Before the intervention and 3 and 6 months after that. Method of measurement: Using ultrasonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hamedanian

Hamedan University of Medical Sciences

mohammad_hamedanian@yahoo.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026